Fibromyalgia Therapeutics Drugs Market 2027 by Product, End User, Impact of covid-19 pandemic. | The Insight Partners

Fibromyalgia Therapeutics Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis By Product ( Cymbalta (Duloxetine), Savella (Milnacipran), Lyrica (Pregabalin), Pancuronium, Others ); End User ( Hospital, Clinic, Others ), Impact of covid-19 pandemic.

Report Code: TIPRE00016395 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Fibromyalgia is a common and complex chronic pain disorder which is characterized by musculoskeletal pain, fatigue, and localized tenderness that affect individuals mentally, physically, as well as socially. Fibromyalgia is primarily caused due to genetic conditions, however actual cause is still unknown. Fatigue, sleeping problems, chronic muscle pain, and tender points are the most common symptoms of fibromyalgia. Symptoms such as headaches, poor concentration, and depression may also be present in a person with fibromyalgia. Symptoms of fibromyalgia can accumulate over time, or some external factors may cause it. Treatments for fibromyalgia includes medications, therapy, regular aerobic exercise, stress reduction, and others. Furthermore, antidepressants or pain killers to relieve stress, anxiety, pain, and exhaustion are used for the treatment of fibromyalgia.

MARKET DYNAMICS

Fibromyalgia Therapeutics Drugs market is driving due to factors such as robust pipeline of novel drugs are under late clinical trial phase and availability of potential customer base. Market players are emphasizing research and development, in order to introduce new products in the market and increase treatment options. Regulatory approval and launch of novel fibromyalgia treatment drugs is expected to enhance fibromyalgia therapeutic drugs market growth over the forecast period. However, factors such as, limited prescriptions written by healthcare professionals and availability of alternative drug products are expected to hamper the market growth.

MARKET SCOPE

The Fibromyalgia Therapeutics Drugs market analysis to 2027 is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Fibromyalgia Therapeutics Drugs market with detailed market segmentation by product and end user. The Fibromyalgia Therapeutics Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Fibromyalgia Therapeutics Drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Fibromyalgia Therapeutics Drugs market is segmented on the basis of products and end user. Based on product, the market is segmented as Cymbalta (Duloxetine), Savella (Milnacipran), Lyrica (Pregabalin), Pancuronium, Others. Based on end user, market is segmented as Hospital, Clinic, Others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Fibromyalgia Therapeutics Drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Fibromyalgia Therapeutics Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Fibromyalgia Therapeutics Drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Fibromyalgia Therapeutics Drugs market in these regions.



Get more information on this report :

MARKET PLAYERS

The report covers key developments in the Fibromyalgia Therapeutics Drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Fibromyalgia Therapeutics Drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for Fibromyalgia Therapeutics Drugs in the global market. Below mentioned is the list of few companies engaged in the Fibromyalgia Therapeutics Drugs market.

The report also includes the profiles of key players in Fibromyalgia Therapeutics Drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Pfizer
- Meiji Seika
- Eli Lilly
- Actavis
- Tonix Pharmaceuticals Holding Corp. (TNXP)
- Innovative Med Concepts
- Daiichi Sankyo
- Pierre Fabre Mdicament
- Boehringer Ingelheim GmbH
- Zynerba Pharmaceuticals

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.



Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Fibromyalgia Therapeutics Drugs Market - By Product
1.3.2 Fibromyalgia Therapeutics Drugs Market - By End User
1.3.3 Fibromyalgia Therapeutics Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. FIBROMYALGIA THERAPEUTICS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. FIBROMYALGIA THERAPEUTICS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. FIBROMYALGIA THERAPEUTICS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. FIBROMYALGIA THERAPEUTICS DRUGS - GLOBAL MARKET OVERVIEW
6.2. FIBROMYALGIA THERAPEUTICS DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. FIBROMYALGIA THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. CYMBALTA (DULOXETINE)
7.3.1. Overview
7.3.2. Cymbalta (Duloxetine) Market Forecast and Analysis
7.4. SAVELLA (MILNACIPRAN)
7.4.1. Overview
7.4.2. Savella (Milnacipran) Market Forecast and Analysis
7.5. LYRICA (PREGABALIN)
7.5.1. Overview
7.5.2. Lyrica (Pregabalin) Market Forecast and Analysis
7.6. PANCURONIUM
7.6.1. Overview
7.6.2. Pancuronium Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. FIBROMYALGIA THERAPEUTICS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL
8.3.1. Overview
8.3.2. Hospital Market Forecast and Analysis
8.4. CLINIC
8.4.1. Overview
8.4.2. Clinic Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. FIBROMYALGIA THERAPEUTICS DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Fibromyalgia Therapeutics Drugs Market Overview
9.1.2 North America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis
9.1.3 North America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Product
9.1.4 North America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By End User
9.1.5 North America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Fibromyalgia Therapeutics Drugs Market
9.1.5.1.1 United States Fibromyalgia Therapeutics Drugs Market by Product
9.1.5.1.2 United States Fibromyalgia Therapeutics Drugs Market by End User
9.1.5.2 Canada Fibromyalgia Therapeutics Drugs Market
9.1.5.2.1 Canada Fibromyalgia Therapeutics Drugs Market by Product
9.1.5.2.2 Canada Fibromyalgia Therapeutics Drugs Market by End User
9.1.5.3 Mexico Fibromyalgia Therapeutics Drugs Market
9.1.5.3.1 Mexico Fibromyalgia Therapeutics Drugs Market by Product
9.1.5.3.2 Mexico Fibromyalgia Therapeutics Drugs Market by End User
9.2. EUROPE
9.2.1 Europe Fibromyalgia Therapeutics Drugs Market Overview
9.2.2 Europe Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis
9.2.3 Europe Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Product
9.2.4 Europe Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By End User
9.2.5 Europe Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Fibromyalgia Therapeutics Drugs Market
9.2.5.1.1 Germany Fibromyalgia Therapeutics Drugs Market by Product
9.2.5.1.2 Germany Fibromyalgia Therapeutics Drugs Market by End User
9.2.5.2 France Fibromyalgia Therapeutics Drugs Market
9.2.5.2.1 France Fibromyalgia Therapeutics Drugs Market by Product
9.2.5.2.2 France Fibromyalgia Therapeutics Drugs Market by End User
9.2.5.3 Italy Fibromyalgia Therapeutics Drugs Market
9.2.5.3.1 Italy Fibromyalgia Therapeutics Drugs Market by Product
9.2.5.3.2 Italy Fibromyalgia Therapeutics Drugs Market by End User
9.2.5.4 Spain Fibromyalgia Therapeutics Drugs Market
9.2.5.4.1 Spain Fibromyalgia Therapeutics Drugs Market by Product
9.2.5.4.2 Spain Fibromyalgia Therapeutics Drugs Market by End User
9.2.5.5 United Kingdom Fibromyalgia Therapeutics Drugs Market
9.2.5.5.1 United Kingdom Fibromyalgia Therapeutics Drugs Market by Product
9.2.5.5.2 United Kingdom Fibromyalgia Therapeutics Drugs Market by End User
9.2.5.6 Rest of Europe Fibromyalgia Therapeutics Drugs Market
9.2.5.6.1 Rest of Europe Fibromyalgia Therapeutics Drugs Market by Product
9.2.5.6.2 Rest of Europe Fibromyalgia Therapeutics Drugs Market by End User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Fibromyalgia Therapeutics Drugs Market Overview
9.3.2 Asia-Pacific Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By End User
9.3.5 Asia-Pacific Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Fibromyalgia Therapeutics Drugs Market
9.3.5.1.1 Australia Fibromyalgia Therapeutics Drugs Market by Product
9.3.5.1.2 Australia Fibromyalgia Therapeutics Drugs Market by End User
9.3.5.2 China Fibromyalgia Therapeutics Drugs Market
9.3.5.2.1 China Fibromyalgia Therapeutics Drugs Market by Product
9.3.5.2.2 China Fibromyalgia Therapeutics Drugs Market by End User
9.3.5.3 India Fibromyalgia Therapeutics Drugs Market
9.3.5.3.1 India Fibromyalgia Therapeutics Drugs Market by Product
9.3.5.3.2 India Fibromyalgia Therapeutics Drugs Market by End User
9.3.5.4 Japan Fibromyalgia Therapeutics Drugs Market
9.3.5.4.1 Japan Fibromyalgia Therapeutics Drugs Market by Product
9.3.5.4.2 Japan Fibromyalgia Therapeutics Drugs Market by End User
9.3.5.5 South Korea Fibromyalgia Therapeutics Drugs Market
9.3.5.5.1 South Korea Fibromyalgia Therapeutics Drugs Market by Product
9.3.5.5.2 South Korea Fibromyalgia Therapeutics Drugs Market by End User
9.3.5.6 Rest of Asia-Pacific Fibromyalgia Therapeutics Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Fibromyalgia Therapeutics Drugs Market by Product
9.3.5.6.2 Rest of Asia-Pacific Fibromyalgia Therapeutics Drugs Market by End User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Fibromyalgia Therapeutics Drugs Market Overview
9.4.2 Middle East and Africa Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By End User
9.4.5 Middle East and Africa Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Fibromyalgia Therapeutics Drugs Market
9.4.5.1.1 South Africa Fibromyalgia Therapeutics Drugs Market by Product
9.4.5.1.2 South Africa Fibromyalgia Therapeutics Drugs Market by End User
9.4.5.2 Saudi Arabia Fibromyalgia Therapeutics Drugs Market
9.4.5.2.1 Saudi Arabia Fibromyalgia Therapeutics Drugs Market by Product
9.4.5.2.2 Saudi Arabia Fibromyalgia Therapeutics Drugs Market by End User
9.4.5.3 U.A.E Fibromyalgia Therapeutics Drugs Market
9.4.5.3.1 U.A.E Fibromyalgia Therapeutics Drugs Market by Product
9.4.5.3.2 U.A.E Fibromyalgia Therapeutics Drugs Market by End User
9.4.5.4 Rest of Middle East and Africa Fibromyalgia Therapeutics Drugs Market
9.4.5.4.1 Rest of Middle East and Africa Fibromyalgia Therapeutics Drugs Market by Product
9.4.5.4.2 Rest of Middle East and Africa Fibromyalgia Therapeutics Drugs Market by End User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Fibromyalgia Therapeutics Drugs Market Overview
9.5.2 South and Central America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis
9.5.3 South and Central America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Product
9.5.4 South and Central America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By End User
9.5.5 South and Central America Fibromyalgia Therapeutics Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Fibromyalgia Therapeutics Drugs Market
9.5.5.1.1 Brazil Fibromyalgia Therapeutics Drugs Market by Product
9.5.5.1.2 Brazil Fibromyalgia Therapeutics Drugs Market by End User
9.5.5.2 Argentina Fibromyalgia Therapeutics Drugs Market
9.5.5.2.1 Argentina Fibromyalgia Therapeutics Drugs Market by Product
9.5.5.2.2 Argentina Fibromyalgia Therapeutics Drugs Market by End User
9.5.5.3 Rest of South and Central America Fibromyalgia Therapeutics Drugs Market
9.5.5.3.1 Rest of South and Central America Fibromyalgia Therapeutics Drugs Market by Product
9.5.5.3.2 Rest of South and Central America Fibromyalgia Therapeutics Drugs Market by End User
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL FIBROMYALGIA THERAPEUTICS DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. FIBROMYALGIA THERAPEUTICS DRUGS MARKET, KEY COMPANY PROFILES
12.1. PFIZER
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. MEIJI SEIKA
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ELI LILLY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ACTAVIS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. TONIX PHARMACEUTICALS HOLDING CORP. (TNXP)
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. INNOVATIVE MED CONCEPTS
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. DAIICHI SANKYO
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. PIERRE FABRE MDICAMENT
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BOEHRINGER INGELHEIM GMBH
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ZYNERBA PHARMACEUTICALS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Pfizer
2. Meiji Seika
3. Eli Lilly
4. Actavis
5. Tonix Pharmaceuticals Holding Corp. (TNXP)
6. Innovative Med Concepts
7. Daiichi Sankyo
8. Pierre Fabre Mdicament
9. Boehringer Ingelheim GmbH
10. Zynerba Pharmaceuticals
TIPRE00016395
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking